Review
Oncology
Soudeh Ghafouri-Fard, Mohammad Taheri, Aria Baniahmad
Summary: Members of the ING family, with their conserved plant homeodomain, play a role in regulating histone modifications and cellular senescence. Different ING members are associated with specific histone modifications and can induce cellular senescence in both normal and cancer cells. This review provides an overview of the current knowledge about the regulatory activity of ING proteins in cellular senescence.
Article
Biochemistry & Molecular Biology
Mariola Ferreras-Gutierrez, Belen Chaves-Arquero, Amaia Gonzalez-Magana, Nekane Merino, Ignacio Amusategui-Mateu, Sonia Huecas, Francisco J. Medrano, Francisco J. Blanco
Summary: Proteins of the ING family regulate chromatin transcription by recruiting remodeling complexes to sites with H3K4me3 modification. ING3, an oncoprotein, facilitates histone acetylation and forms homodimers with an antiparallel coiled-coil fold. The crystal structure of ING3's PHD domain reveals its interaction with H3K4me3 and the impact of mutations on histone recognition.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
(2023)
Article
Immunology
Sophia Y. Y. Mah, Hannah K. Vanyai, Yuqing Yang, Anne K. Voss, Tim Thomas
Summary: ING5 is a component of KAT6A and KAT7 histone lysine acetylation complexes and functions as a 'reader' and adaptor protein by binding to trimethylated histone H3 lysine 4. The absence of ING5 during development leads to decreased foetal liver cellularity, hematopoietic stem cell numbers, and perturbed erythropoiesis. Additionally, Ing5(-/-) pups display hypoplastic spleens. However, competitive transplantation experiments show that the defects observed during the foetal stage are not cell intrinsic, suggesting that ING5 is dispensable for normal hematopoiesis but may be required for timely foetal hematopoiesis in a cell-extrinsic manner.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Cell Biology
Hua-chuan Zheng, Hang Xue, Hua-mao Jiang
Summary: As a Class II tumor suppressor, ING5 regulates the expression of target genes by forming complexes with other proteins. ING5 inhibits proliferation, migration, invasion, and tumor growth of cancer cells by suppressing multiple signaling pathways and chemoresistance. The expression of ING5 during carcinogenesis is inversely associated with prognosis.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Lin He, Ruorong Yan, Ziran Yang, Yue Zhang, Xinhua Liu, Jianguo Yang, Xujun Liu, Xiaoping Liu, Lu Xia, Yue Wang, Jiajing Wu, Xiaodi Wu, Lin Shan, Xiaohan Yang, Jing Liang, Yongfeng Shang, Luyang Sun
Summary: The F-box protein JFK promotes lipid accumulation in adipose tissue, leading to the development of metabolic syndrome. Knockout of JFK gene in mice can resist diet-induced metabolic dysfunctions. The interaction between JFK and ING5 disrupts AMPK activity and fatty acid beta-oxidation, suppressing hepatic lipid catabolism and contributing to obesity and metabolic syndrome.
Article
Multidisciplinary Sciences
Lee-Hyang Kim, Ja-Young Kim, Yu-Ying Xu, Mi Ae Lim, Bon Seok Koo, Jung Hae Kim, Sung-Eun Yoon, Young -Joon Kim, Kwang-Wook Choi, Jae Won Chang, Sung -Tae Hong
Summary: A study found that Translationally controlled tumor protein (TCTP) and ING5 activator are the unique binding partners of the MOZ/MORF histone acetyltransferase complex. TCTP regulates the nuclear translocation of ING5 and the chromatin localization of Enok, thus controlling the acetylation of H3K23. This study reveals the important role of TCTP in human tumorigenesis.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2023)
Article
Oncology
Xiaoyan Wu, Chuang Chen, Bin Luo, Dandan Yan, Honglin Yan, Fangfang Chen, Feng Guan, Hao Wu, Jingping Yuan
Summary: ING3 expression varies significantly between normal breast tissues and breast cancer tissues, with reduced nuclear ING3 associated with an adverse prognosis in breast cancer patients. These findings provide valuable insights into the pathogenesis and clinical management of breast cancer, highlighting nuclear ING3 as a potential independent prognostic predictor and a novel avenue for breast cancer research.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Hua-chuan Zheng, Hang Xue, Xin Wu, Hai-lan Xu, En-hong Zhao, Zheng-guo Cui
Summary: ING5 targets histone acetyltransferase or histone deacetylase complexes for local chromatin remodeling and has suppressive effects on gastric cancer. SRF and YY1 interact with the promoter of ING5, up-regulating its expression in gastric cancer. Overexpression of ING5, SRF, and YY1 is associated with worse prognosis in gastric cancer patients. SAHA treatment enhances migration and invasion of ING5 transfectants. ING5 deletion contributes to gastric carcinogenesis and histogenesis.
FRONTIERS IN ONCOLOGY
(2022)
Article
Chemistry, Multidisciplinary
Qian Gou, Huiqing Chen, Mingjun Chen, Juanjuan Shi, Jianhua Jin, Qian Liu, Yongzhong Hou
Summary: Immune cells play a role in protecting against tumor progression, while aberrant expression of PD-L1 in cancer cells leads to tumor immune escape. This study found that ING4 induces the autophagic degradation of PD-L1, inhibiting immune escape in NSCLC. However, high expression of CK2 was found to correlate with low ING4 protein levels in NSCLC. Further analysis revealed that CK2 induces the phosphorylation of ING4-S150, leading to its degradation by JFK ubiquitin ligase. In contrast, CK2 gene knockout increased ING4 protein stability and T cell activity, inhibiting NSCLC immune escape. Additionally, the combination of a CK2 inhibitor and PD-1 antibody effectively enhanced antitumor immunotherapy.
Article
Oncology
Junjie Jiang, Hui-Ju Wang, Xiao-Zhou Mou, Huanqing Zhang, YiZhen Chen, Zhi-Ming Hu
Summary: KAT6B expression is significantly lower in HCC tissues compared to normal tissues, and its low expression is associated with gender, AFP level, and tumor size. The study suggests that KAT6B may be a potential tumor suppressor in liver cancer.
TECHNOLOGY IN CANCER RESEARCH & TREATMENT
(2021)
Article
Oncology
Liangliang Zhang, Dagang Zhu, Jiwen Jiang, Zhenyu Min, Zhenzhong Fa
Summary: Our findings demonstrate that MDM2 regulates CRC cell growth and chemoresistance by modifying the transcription factor ING3 through ubiquitination-proteasome pathway degradation.
Article
Medicine, Research & Experimental
Huimeng Li, Hengyu Zhang, Xin Tan, Dequan Liu, Rong Guo, Maohua Wang, Yiyin Tang, Kai Zheng, Wenlin Chen, Hongwan Li, Mingjian Tan, Ke Wang, Rui Liu, Shicong Tang
Summary: ING3 has been identified as a potential cancer drug target. This study found that ING3 expression is significantly lower in breast cancer tissues compared to normal tissues. Overexpression of ING3 inhibited the migratory and invasive abilities of breast cancer cells, potentially through regulating the PI3K/AKT, JAK/STAT, NF-kappa B, and Wnt/beta-catenin pathways. Further studies are needed to fully understand how ING3 may regulate the biological behavior of breast cancer cells.
EXPERIMENTAL AND THERAPEUTIC MEDICINE
(2021)
Article
Oncology
Sophie Bartsch, Kimia Mirzakhani, Laura Neubert, Alexander Stenzel, Marzieh Ehsani, Mohsen Esmaeili, Thanakorn Pungsrinont, Merve Kacal, Seyed Mohammad Mahdi Rasa, Julia Kallenbach, Divya Damodaran, Federico Ribaudo, Marc-Oliver Grimm, Francesco Neri, Aria Baniahmad
Summary: The expression of human telomerase reverse transcriptase subunit (hTERT) is hormonally controlled, with androgen treatment suppressing hTERT expression in prostate cancer cells. This inhibition and activation of hTERT by androgens is mediated by androgen receptor (AR) co-repressors ING1 and ING2. This reveals a dual role of AR in controlling hTERT expression during prostate cancer tumorigenesis.
Article
Polymer Science
Longxing Niu, Guo Chen, Yanfei Feng, Xueping Liu, Peng Pan, Linling Huang, Ying Guo, Mingzhong Li
Summary: Polyethyleneimine (PEI) was grafted onto Bombyx mori silk fibroin to prepare cationized silk fibroin, which effectively transfected lung cancer cells with high efficiency and low toxicity. This gene delivery system has potential applications in lung cancer gene therapy.
Article
Multidisciplinary Sciences
Bercin K. Cenik, Christie C. Sze, Caila A. Ryan, Siddhartha Das, Kaixiang Cao, Delphine Douillet, Emily J. Rendleman, Didi Zha, Nabiha Haleema Khan, Elizabeth Bartom, Ali Shilatifard
Summary: This study reveals that Set1A/COMPASS and ING5 may play crucial roles in regulating the self-renewal and differentiation status of ESCs.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2022)
Article
Oncology
Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen, Niels Reinmuth, Katsuyuki Hotta, Dmytro Trukhin, Galina Statsenko, Maximilian J. Hochmair, Mustafa Ozguroglu, Jun Ho Ji, Marina Chiara Garassino, Oleksandr Voitko, Artem Poltoratskiy, Santiago Ponce, Francesco Verderame, Libor Havel, Igor Bondarenko, Andrzej Kazarnowicz, Gyorgy Losonczy, Nikolay V. Conev, Jon Armstrong, Natalie Byrne, Piruntha Thiyagarajah, Haiyi Jiang, Luis Paz-Ares
Summary: The study showed that first-line treatment with durvalumab plus platinum-etoposide resulted in sustained improvement in overall survival, while the addition of tremelimumab to this combination did not significantly enhance efficacy. These findings support the use of durvalumab plus platinum-etoposide as a new standard of care for extensive-stage small-cell lung cancer.
Article
Oncology
H. Blons, J-B Oudart, J-P Merlio, D. Debieuvre, F. de Fraipont, C. Audigier-Valette, F. Escande, S. Hominal, P-P Bringuier, S. Fraboulet-Moreau, L. Ouafik, D. Moro-Sibilot, A. Lemoine, A. Langlais, P. Missy, F. Morin, P-J Souquet, F. Barlesi, J. Cadranel, M. Beau-Faller
Summary: Tumor mutation screening is crucial for patients with stage IV NSCLC, and identifying co-occurring alterations, such as PTEN, ATM, IDH1, and KRAS mutations, can impact the response and prognosis to first line EGFR TKI therapy. These findings may offer new treatment options for patients with unfavorable genotypes to improve their initial treatment responses.
Article
Oncology
S. Peters, J-L Pujol, U. Dafni, M. Domine, S. Popat, M. Reck, J. Andrade, A. Becker, D. Moro-Sibilot, A. Curioni-Fontecedro, O. Molinier, K. Nackaerts, A. Insa Molla, R. Gervais, G. Lopez Vivanco, J. Madelaine, J. Mazieres, M. Faehling, F. Griesinger, M. Majem, J. L. Gonzalez Larriba, M. Provencio Pulla, K. Vervita, H. Roschitzki-Voser, B. Ruepp, P. Mitchell, R. A. Stahel, C. Le Pechoux, D. De Ruysscher
Summary: The STIMULI trial did not demonstrate improvement in PFS with nivolumab-ipilimumab consolidation after chemo-radiotherapy in limited-disease small-cell lung cancer. The higher rates of grade >= 3 adverse events and treatment discontinuation in the experimental arm may have influenced the efficacy results.
ANNALS OF ONCOLOGY
(2022)
Article
Oncology
Julien Mazieres, Claire Lafitte, Charles Ricordel, Laurent Greillier, Elodie Negre, Gerard Zalcman, Charlotte Domblides, Jeannick Madelaine, Jaafar Bennouna, Celine Mascaux, Denis Moro-Sibilot, Francois Pinquie, Alexis B. Cortot, Josiane Otto, Jacques Cadranel, Alexandra Langlais, Franck Morin, Virginie Westeel, Benjamin Besse
Summary: This study evaluated the efficacy of a triple therapy with HER2-targeted antibodies and docetaxel in HER2-mutated NSCLC patients, demonstrating feasibility and effectiveness of this approach, highlighting the potential benefit of HER2 antibody-based strategy in this subset of patients.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Naoyuki Nogami, Fabrice Barlesi, Mark A. Socinski, Martin Reck, Christian A. Thomas, Federico Cappuzzo, Tony S. K. Mok, Gene Finley, Joachim G. Aerts, Francisco Orlandi, Denis Moro-Sibilot, Robert M. Jotte, Daniil Stroyakovskiy, Liza C. Villaruz, Delvys Rodriguez-Abreu, Darren Wan-Teck Lim, David Merritt, Shelley Coleman, Anthony Lee, Geetha Shankar, Wei Yu, Ilze Bara, Makoto Nishio
Summary: This study presents the final overall survival (OS) analyses for EGFR mutations and liver or brain metastases subgroups in the IMpower150 study. The results show that ABCP has sustained OS improvements compared to BCP in sensitizing EGFR mutations and baseline liver metastases subgroups. However, ACP does not provide a survival benefit in these subgroups compared to BCP. The study also suggests further investigation into the impact of ABCP on delaying the development of new brain lesions.
JOURNAL OF THORACIC ONCOLOGY
(2022)
Article
Oncology
Pierre-Jean Souquet, Clarisse Audigier-Valette, Olivier Molinier, Alexis Cortot, Jacques Margery, Lionel Moreau, Radj Gervais, Fabrice Barlesi, Eric Pichon, Gerard Zalcman, Patrick Dumont, Nicolas Girard, Michel Poudenx, Julien Mazieres, Jacques Cadranel, Didier Debieuvre, Jerome Dauba, Alexandra Langlais, Franck Morin, Denis Moro-Sibilot, Virginie Westeel, Maurice Perol
Summary: Adapting maintenance strategy according to response to induction chemotherapy does not improve patient outcome in advanced non-squamous non-small cell lung cancer.
Article
Oncology
Anne Mc Leer, Matthieu Foll, Marie Brevet, Martine Antoine, Silvia Novello, Julie Mondet, Jacques Cadranel, Nicolas Girard, Matteo Giaj Levra, Pierre Demontrond, Clarisse Audigier-Valette, Eric Letouze, Sylvie Lantuejoul, Lynnette Fernandez-Cuesta, Denis Moro-Sibilot
Summary: In EGFR-LUAD patients who develop resistance to EGFR-TKIs and undergo histological transformation to SCLC, mutations in TP53 and alterations in the Rb pathway are common genetic changes predisposing to SCLC transformation. Additionally, TERT amplification has been identified as another common genetic mechanism acquired during SCLC transformation in this subset of patients.
Article
Nanoscience & Nanotechnology
Clement Goubault, Ulrich Jarry, Megane Bostoen, Pierre-Antoine Eliat, Myrtil L. Kahn, Remy Pedeux, Thierry Guillaudeux, Fabienne Gauffre, Soizic Chevance
Summary: This study evaluated the potentiating effect of hollow shells made of gold and iron oxide nanoparticles on radiotherapy for glioblastoma. The results showed a significant effect of gold nanoparticles in radiotherapy, while iron oxide had no beneficial effects. The study also found that injected hybridosomes(R) remained near the brain tumor for several days in vivo. These findings provide a proof-of-concept for the effectiveness of hybridosomes(R) as tools for the development of combined therapies.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
(2022)
Article
Biochemistry & Molecular Biology
Lisa Derosa, Bertrand Routy, Andrew Maltez Thomas, Valerio Iebba, Gerard Zalcman, Sylvie Friard, Julien Mazieres, Clarisse Audigier-Valette, Denis Moro-Sibilot, Francois Goldwasser, Carolina Alves Costa Silva, Safae Terrisse, Melodie Bonvalet, Arnaud Scherpereel, Herve Pegliasco, Corentin Richard, Francois Ghiringhelli, Arielle Elkrief, Antoine Desilets, Felix Blanc-Durand, Fabio Cumbo, Aitor Blanco, Romain Boidot, Sandy Chevrier, Romain Daillere, Guido Kroemer, Laurie Alla, Nicolas Pons, Emmanuelle Le Chatelier, Nathalie Galleron, Hugo Roume, Agathe Dubuisson, Nicole Bouchard, Meriem Messaoudene, Damien Drubay, Eric Deutsch, Fabrice Barlesi, David Planchard, Nicola Segata, Stephanie Martinez, Laurence Zitvogel, Jean-Charles Soria, Benjamin Besse
Summary: In addition to PD-L1 expression, biomarkers for predicting the response to immune checkpoint inhibitors (ICIs) in non-small-cell lung cancer (NSCLC) are needed. This study found that fecal Akkermansia muciniphila (Akk) was associated with clinical benefit of ICI treatment in NSCLC patients, independent of PD-L1 expression and other factors. The relative abundance of Akk in the gut microbiome may serve as a potential biomarker for patient stratification.
Article
Oncology
O. Molinier, B. Besse, F. Barlesi, C. Audigier-Valette, S. Friard, I Monnet, G. Jeannin, J. Mazieres, J. Cadranel, J. Hureaux, W. Hilgers, E. Quoix, B. Coudert, D. Moro-Sibilot, E. Fauchon, V Westeel, P. Brun, A. Langlais, F. Morin, P. J. Souquet, N. Girard
Summary: This study examined the efficacy and safety of nivolumab, an immune checkpoint inhibitor, in patients with advanced refractory non-small-cell lung cancer. The results showed that nivolumab had a significant effect, and the study identified prognostic factors that influenced the patients' survival rates.
Article
Biology
Alexandra Papaioannou, Federica Centonze, Alice Metais, Marion Maurel, Luc Negroni, Matias Gonzalez-Quiroz, Sayyed Jalil Mahdizadeh, Gabriella Svensson, Ensieh Zare, Alice Blondel, Albert C. Koong, Claudio Hetz, Remy Pedeux, Michel L. Tremblay, Leif A. Eriksson, Eric Chevet
Summary: The IRE1 alpha RNase regulatory network is dynamically regulated by tyrosine kinases and phosphatases. The extent of RtcB tyrosine phosphorylation determines cell adaptive or death outputs.
LIFE SCIENCE ALLIANCE
(2022)
Article
Oncology
Simon Baldacci, Benjamin Besse, Virginie Avrillon, Bertrand Mennecier, Julien Mazieres, Pascale Dubray-Longeras, Alexis B. Cortot, Renaud Descourt, Helene Doubre, Xavier Quantin, Michael Duruisseaux, Isabelle Monnet, Denis Moro-Sibilot, Jacques Cadranel, Christelle Clement-Duchene, Sophie Cousin, Charles Ricordel, Patrick Merle, Josiane Otto, Sophie Schneider, Alexandra Langlais, Franck Morin, Virginie Westeel, Nicolas Girard
Summary: In this study, the researchers evaluated the treatment sequencing, efficacy, and safety of lorlatinib in patients with ALK+ NSCLC through the French Expanded Access Program. The results showed that lorlatinib provided significant clinical benefit and high intracerebral antitumor activity in heavily pretreated patients with ALK+ NSCLC.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
Elodie Maille, Jerome Levallet, Fatemeh Dubois, Martine Antoine, Claire Danel, Christian Creveuil, Julien Mazieres, Jacques Margery, Laurent Greillier, Valerie Gounant, Denis Moro-Sibilot, Olivier Molinier, Herve Lena, Isabelle Monnet, Emmanuel Bergot, Alexandra Langlais, Franck Morin, Arnaud Sherpereel, Gerard Zalcman, Guenaelle Levallet
Summary: This study suggests that high cytosolic AREG expression is associated with better prognosis in malignant pleural mesothelioma (MPM). However, tumor cells fail to correctly process and release AREG, leading to inconsistency between its expression in plasma and tumor cells. Therefore, mesothelioma cell AREG content may serve as a prognostic marker.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Article
Oncology
Charly Gutierrez, Xavier Pinson, Kathleen Jarnouen, Marine Charpentier, Raphael Pineau, Laetitia Lallement, Remy Pedeux
Summary: Urinary cytology is a non-invasive and easy-to-collect method for detecting bladder cancer. It is effective for high-grade bladder cancer, but less effective for low-grade cancer. Recent research has found that the fluorescent properties of urothelial tumor cells in urinary cytology, known as peri-membrane fluorescence, can improve early detection of bladder cancer.
Article
Oncology
N. Girard, S. Galland-Girodet, V Avrillon, B. Besse, M. Duruisseaux, J. Cadranel, J. Otto, A. Prevost, B. Roch, J. Bennouna, K. Bouledrak, M. Coudurier, T. Egenod, R. Lamy, C. Ricordel, D. Moro-Sibilot, L. Odier, J. Tillon-Strozyk, G. Zalcman, P. Missy, V Westeel, S. Baldacci
Summary: This study investigates the efficacy and safety of lorlatinib in patients with ROS1-rearranged non-small-cell lung cancer (ROS1thorn NSCLC) treated through an expanded access program. The results suggest that lorlatinib is a major treatment option for advanced refractory ROS1thorn NSCLC in the treatment strategy.